NCT00135343 - A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions

HIV Infections

Interventions

DRUG

Atazanvir/ritonavir + efavirenz

Capsules (ATV and RTV) Tablets (EFV), Oral, ATV 300 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.

DRUG

Atazanvir/ritonavir + efavirenz

Capsules (ATV and RTV) Tablets (EFV), Oral ATV 400 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.

Trial Locations (15)

Local Institution, San Francisco

Local Institution, Washington D.C.

Local Institution, Atlantis

Local Institution, Orlando

Local Institution, South Miami

Local Institution, Tampa

Local Institution, New Orleans

Local Institution, Boston

Local Institution, Berkley

Local Institution, St Louis

Local Institution, Huntersville

Local Institution, Clumbia

Local Institution, Austin

Local Institution, Dallas

Local Institution, Hampton